MSH2 and neoplasm: Patients with EAC and those with dysplasia did not have loss of MSH2/MSH6 expression, so we can conclude that EAC is a sporadic tumor, rather than a tumor associated with HNPCC, and that only MLH1/PMS2 mutation is of interest in patient surveillance.